Top Line: Altris AI has unveiled additional quantification features for Fluids and Geographic Atrophy (GA) tracking on its web platform. Altris AI currently detects over 70 retina pathologies and biomarkers.
Close Up: The presence of fluids such as Intraretinal Cystoid Fluid (IRC), Diffuse Edema, Subretinal Fluid (SRF) and Serous Retinal Pigment Epithelium (RPE) Detachment are critical biomarkers for conditions like nAMD, DME, DR and RVO. Accurate detection, quantification and tracking of these fluids are essential for monitoring disease activity, evaluating treatment efficacy, and making informed prognoses. Altris AI says it created specialized and more detailed functions which detect these biomarkers for more specific and accurate tracking. The AI algorithm was additionally trained to work directly with fluids considering the importance of these biomarkers for accurate diagnostics. Altris AI’s advanced algorithms were trained on millions of OCT scans and provide precise and objective fluid analysis. Each of the four fluid types is localized and color-coded for clarity, and quantitative metrics such as volume, area and ETDRS grids (1, 3, and 6 mm) are calculated and presented in mm3 or nanoliters for comprehensive evaluation. The Progression Tracking feature offers historical trend analysis with intuitive visualizations through graphs and percentages.
Altris AI’s updated model is now more robust in detecting the fovea zone and central scan, especially in cases where the center cannot be distinguished due to pathology presence or other reasons. Altris AI says its new model can find an accurate center in 95 percent of cases; in other situations, it can efficiently estimate the center location. 
Finally, Further Progression Tracking enhances GA management by visualizing changes over time, supporting timely and accurate treatment decisions. By streamlining workflows and providing actionable insights, this feature helps ECPs make informed choices and potentially preserve vision in GA patients.
Vital Stats: Maria Znamenska, MD, PhD, and a chief medical officer at Altris AI, said, “We listened to our clients and introduced Fluid and GA tracking features. In 2025, eyecare specialists will have the tools to combine their expertise with next-generation AI technology to tackle conditions that threaten vision effectively. Our formula is simple: detect, quantify, and track fluids, GA, and 70+ retina pathologies and biomarkers for better patient outcomes.”
www.altris.ai